872018-02-5

Basic information

• Product Name: tert-butyl 4-cyano-2-fluorobenzoate
• Synonyms: tert-butyl 4-cyano-2-fluorobenzoate
• CAS NO: 872018-02-5
• Molecular Weight: 221.231
• Mol File: 872018-02-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-cyano-2-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-cyano-2-fluorobenzoate(872018-02-5)
• EPA Substance Registry System: tert-butyl 4-cyano-2-fluorobenzoate(872018-02-5)

Safety Data

• Hazardous Substances Data: 872018-02-5(Hazardous Substances Data)

Upstream product

• 164149-28-4 4-cyano-2-fluorobenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 872018-03-6 tert-butyl 4-cyano-2-(ethylamino)benzoate 
• 1371592-02-7 N-cyclopenta-3-en-1-yl-4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluorobenzamide 
• 1371591-49-9 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-N-[(2S)-2,3-dihydroxypropyl]-2-fluorobenzamide 
• 1371591-50-2 N-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluorobenzamide 
• 1371591-51-3 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]benzamide 
• 1371591-55-7 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 
• 1371591-65-9 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(1S)-3-hydroxy-1-(hydroxymethyl)propyl]benzamide 
• 1371591-67-1 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-N-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]-2-fluorobenzamide 
• 1371591-72-8 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-N-[(1R,2R)-2,3-dihydroxy-1-methylpropyl]-2-fluorobenzamide 
• 1371591-92-2 tert-butyl 4-(5-{(1R)-1-[4-(cyclobutylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluorobenzoate 
• 1371591-77-3 tert-butyl 4-{5-[(1S)-1-acetoxypropyl]-1,2,4-oxadiazol-3-yl}-2-fluorobenzoate 
• 1371591-78-4 tert-butyl 2-fluoro-4-{5-[(1S)-1-hydroxypropyl]-1,2,4-oxadiazol-3-yl}benzoate 
• 1371591-79-5 tert-butyl 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluorobenzoate 
• 1371591-80-8 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluorobenzoic acid 

Relevant articles and documents

NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING

The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join

ACYLBENZENE DERIVATIVE

Provided are compounds having an excellent hypoglycemic action and a β cell- or pancreas-protecting action or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.

FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.